The Return of Part 11
This article was originally published in The Gold Sheet
FDA July 7 alerted industry that the agency will soon begin conducting inspections focused on compliance with its March 1997 Part 11 rule on electronic records and electronic signatures
You may also be interested in...
Six of FDA's last nine drug GMP warning letters went to contract manufacturing facilities, including firms making OTC drugs and dietary supplements.
FDA sent six of its last nine drug GMP warning letters to contract manufacturing facilities. Most of the letters emphasized corporate accountability, and many went directly to CEOs.
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.